Articles tagged "IVIG"

2021 American Transplant Congress
Outcomes of IVIG Monotherapy for Donor-Specific Antibodies After Lung Transplantation
K. Spence, S. Heeney, M. Morrison, S. A. Rega, F. D. Irene, K. B. Harrison, C. M. Shaver
Vanderbilt University Medical Center, Nashville, TN
*Purpose: De novo donor-specific antibodies (DSA) are a risk factor for antibody mediated rejection (AMR) and poor clinical outcomes after lung transplant (LT). Intravenous immune…
2021 American Transplant Congress
Intravenous Immunoglobulin in Heart Transplant Recipients with Hypogammaglobulinemia and Infection
J. Hoang, D. Nguyen, E. Graviss, M. Moaddab, A. Guha, J. Krisl
Houston Methodist Hospital, Houston, TX
*Purpose: Hypogammaglobulinemia (HGG) is a complication of solid organ transplantation which has been associated with increased risk of infections. HGG is commonly defined as a…
2020 American Transplant Congress
Posttransplant Prophylactic Therapy with IVIG/Plasmapheresis in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies
T. V. Sandes-Freitas, B. Neri, J. Junqueira Junior, T. Leite, M. Sales, R. Esmeraldo
Hospital Geral de Fortaleza, Fortaleza, Brazil
*Purpose: Patients with high levels of preformed donor-specific antibodies (DSA) are often not considered for kidney transplantation (KT), despite negative CDC-crossmatch, mainly in regions where…
2020 American Transplant Congress
Osmotic Nephropathy from a Non-Sucrose Based IVIG
S. Reddy, L. Kodali
Nephrology, Mayo Clinic, Phoenix, AZ
*Purpose: We present a case of acute renal failure and hyperkalemia due to osmotic nephropathy from a non-sucrose based IVIG infusion therapy.*Methods: A 67-year-old man…
2019 American Transplant Congress
Intravenous Immunoglobulin Significantly Reduces Bioavailability of Concomitantly Administered Anti-C5 Monoclonal Antibodies
S. C. Jordan¹, K. Kucher², M. Bagger², H. Hockey³, K. Wagner⁴, N. Ammerman¹, J. Choi¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Biometrics Matters Ltd, Hamilton, New Zealand, ⁴Novartis Institutes for BioMedical Research, Cambridge, MA
*Purpose: Awareness of drug-drug interactions is critical in management of organ transplant recipients. However, there is little understanding of the possibility of biologic agents interfering…
2019 American Transplant Congress
Predictors of Response to Intravenous Immunoglobulin for Treatment of Polyoma Nephropathy
S. Sethi, A. Vo, A. Peng, R. Najjar, K. Lim, S. Jordan, E. Huang
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: BK nephropathy is an important cause of allograft dysfunction or loss. IVIg is hypothesized to be effective by providing passive immunity to BK virus…
2019 American Transplant Congress
Reduction of Circulating DSA: Does It Affect Histology?
M. Gupta¹, E. Edusei¹, S. Tsai², M. Magruder², J. Lee¹, J. Lee¹, C. Hartono¹, T. Muthukumar¹, M. Everly³, D. Dadhania¹
¹Nephrology, New York Presbyterian Weill Cornell, New York, NY, ²New York Presbyterian Weill Cornell, New York, NY, ³Terasaki Research Institute, Los Angeles, CA
*Purpose: De novo donor specific antibodies (dnDSA) are reported in 13-30% of kidney transplant recipients. dnDSA has been associated with antibody mediated rejection (AMR) and…
2019 American Transplant Congress
Desensitization Using Only Polyvalent Immunoglobulins (IVIG) for Kidney Transplantation with Living Donors (LD)
L. R. Ulisses, J. O. Paixão, P. S. Souza, G. Bezerra, H. Rodrigues, N. Panajatopoulos, F. J. De Paula, E. David-Neto, M. C. R Castro
Renal Transplant Service, Renal Transplant Service, Hospital das Clinicas and Laboratory of Immunology-LIM-19, Medical School of te University of São Paulo, São Paulo, Brazil, São Paulo, Brazil
*Purpose: HLA sensitization is a barrier for kidney transplantation. Sensitized patients stay longer on the waiting list and have higher mortality rate and complications while…
2019 American Transplant Congress
Sequential Dosing of Rituximab and IVIg for Desensitization of Highly-HLA Sensitized (HS) Patients Awaiting HLAi Kidney Transplantation
A. A. Vo, E. Huang, S. Williamsons, C. Myers, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, S. C. Jordan
Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Recent observations suggest that the use of IVIg + rituximab has a critical role in modifying allo-reactive B-cells prior to HLAi kidney transplantation, thus…
2019 American Transplant Congress
Pre-emptive Ivig For Dsa Positive Living Donor Kidney Transplant Recipients
B. Abdalla¹, D. Kellner², A. Diaz², Y. Zheng³, E. Reed⁴, Q. J. Zhang⁴
¹Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, ³UCLA Immunogenetics Center, Los Angeles, CA, ⁴Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Intravenous immunoglobulin (IVIG) is used in desensitization regimens to modulate anti-human leukocyte antigen (HLA) donor-specific antibody (DSA) to facilitate transplantation of sensitized patients, however,…